0001104659-16-131384.txt : 20160706 0001104659-16-131384.hdr.sgml : 20160706 20160706212246 ACCESSION NUMBER: 0001104659-16-131384 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160706 FILED AS OF DATE: 20160706 DATE AS OF CHANGE: 20160706 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NELSEN ROBERT CENTRAL INDEX KEY: 0001219042 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161755407 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 4 1 a4.xml 4 X0306 4 2016-07-06 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001219042 NELSEN ROBERT C/O ARCH VENTURE PARTNERS 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 1 0 Common Stock 2016-07-06 4 C 0 266666 A 479999 I See footnote Common Stock 2016-07-06 4 C 0 1333333 A 1813332 I See footnote Common Stock 2016-07-06 4 C 0 2000000 A 3813332 I See footnote Common Stock 2016-07-06 4 C 0 423805 A 4237137 I See footnote Common Stock 2016-07-06 4 P 0 400000 12.50 A 4637137 I See footnote Series A-1 Preferred Stock 2016-07-06 4 C 0 1000000 0 D Common Stock 266666 0 I See footnote Series A-2 Preferred Stock 2016-07-06 4 C 0 5000000 0 D Common Stock 1333333 0 I See footnote Series A-3 Preferred Stock 2016-07-06 4 C 0 7500000 0 D Common Stock 2000000 0 I See footnote Series B Preferred Stock 2016-07-06 4 C 0 1589269 0 D Common Stock 423805 0 I See footnote The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose. /s/Mark McDonnell, as attorney-in-fact for Robert Nelsen 2016-07-06